Skip to main content

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC

*January 2021*

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.

The HER3-directed antibody-drug conjugate (ADC) also had a manageable safety profile at the 5.6-mg/kg dose.

As of April 30, 2020, 57 patients with EGFR-mutant NSCLC from the dose-escalation and dose-expansion portions had been treated with patritumab deruxtecan, 56 of whom were evaluable for response.

The confirmed objective response rate per blinded independent central review was 25% (n = 14; 95% CI, 14.4%-38.4%), which consisted of a 2% complete response rate (n = 1) and a 23% partial response rate (n = 13). The stable disease rate was 45% (n = 25). Read more.